

BD launches high-throughput molecular dx platform in the U.S.

Aug. 26, 2021—[BD](#) has launched its FDA-approved BD COR PX/GX system, a fully automated, high-throughput diagnostic platform that integrates robotics and sample management software algorithms to automate the complete molecular laboratory workflow from sample processing to diagnostic test result.

The BD COR system offers two instruments: the BD COR PX integrates and automates the sample workflow for diagnostic specimens and assays, and the BD COR GX automates specifically the BD Onclarity HPV assay with extended genotyping. The PX instrument will prepare samples by performing preanalytical processing steps and automatically deliver the samples to the GX instrument for analysis. The GX instrument will perform the analytical steps of the BD Onclarity HPV assay, including extraction, amplification and, detection.

The system is modular and scalable and has onboard capacity for reagents and samples that provide six to eight hours of walkaway time.